{"result": {"id": "2e5b69ee-1474-4702-9a7a-cbfb34a6dff9", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "(\"entity\"<|>KRUM H<|>PERSON<|>Krum H is a researcher involved in studies on renal sympathetic denervation for resistant hypertension)\n##\n(\"entity\"<|>SCHLAICH M<|>PERSON<|>Schlaich M is a researcher involved in studies on renal sympathetic denervation for resistant hypertension)\n##\n(\"entity\"<|>WHITBOURN R<|>PERSON<|>Whitbourn R is a researcher involved in studies on renal sympathetic denervation for resistant hypertension)\n##\n(\"entity\"<|>ESLER MD<|>PERSON<|>Esler MD is a researcher involved in the Symplicity HTN-2 trial on renal sympathetic denervation)\n##\n(\"entity\"<|>BHATT DL<|>PERSON<|>Bhatt DL is a researcher involved in trials on renal denervation for resistant hypertension)\n##\n(\"entity\"<|>KANDZARI DE<|>PERSON<|>Kandzari DE is a researcher involved in multiple trials on renal denervation for hypertension)\n##\n(\"entity\"<|>O’NEILL WW<|>PERSON<|>O’Neill WW is a researcher involved in trials on renal denervation for resistant hypertension)\n##\n(\"entity\"<|>VADUGANATHAN M<|>PERSON<|>Vaduganathan M is a researcher involved in long-term outcomes studies of renal denervation)\n##\n(\"entity\"<|>KARIO K<|>PERSON<|>Kario K is a researcher involved in the SPYRAL HTN Global Clinical Trial Program)\n##\n(\"entity\"<|>MAHFOUD F<|>PERSON<|>Mahfoud F is a researcher involved in multiple studies on renal denervation and its effects)\n##\n(\"entity\"<|>TOWNSEND RR<|>PERSON<|>Townsend RR is a researcher involved in the SPYRAL HTN-OFF MED trial)\n##\n(\"entity\"<|>B?HM M<|>PERSON<|>Böhm M is a researcher involved in studies on renal denervation and its long-term outcomes)\n##\n(\"entity\"<|>SCHMIEDER R<|>PERSON<|>Schmieder R is a researcher involved in long-term outcomes studies of renal denervation)\n##\n(\"entity\"<|>AZIZI M<|>PERSON<|>Azizi M is a researcher involved in the RADIANCE-HTN SOLO and TRIO trials)\n##\n(\"entity\"<|>SANGHVI K<|>PERSON<|>Sanghvi K is a researcher involved in the RADIANCE-HTN TRIO trial)\n##\n(\"entity\"<|>SAXENA M<|>PERSON<|>Saxena M is a researcher involved in the RADIANCE-HTN SOLO and TRIO trials)\n##\n(\"entity\"<|>PATHAK A<|>PERSON<|>Pathak A is a researcher involved in studies on alcohol-mediated renal denervation)\n##\n(\"entity\"<|>RUDOLPH UM<|>PERSON<|>Rudolph UM is a researcher involved in studies on alcohol-mediated renal denervation)\n##\n(\"entity\"<|>WEBER MA<|>PERSON<|>Weber MA is a researcher involved in the TARGET BP I trial)\n##\n(\"entity\"<|>KALARUS Z<|>PERSON<|>Kalarus Z is a researcher involved in studies on pacemaker-based cardiac neuromodulation therapy)\n##\n(\"entity\"<|>MERKELY B<|>PERSON<|>Merkely B is a researcher involved in studies on pacemaker-based cardiac neuromodulation therapy)\n##\n(\"entity\"<|>NEU?IL P<|>PERSON<|>Neušil P is a researcher involved in studies on pacemaker-based cardiac neuromodulation therapy)\n##\n(\"entity\"<|>SYMPLICITY HTN-2 INVESTIGATORS<|>ORGANIZATION<|>The Symplicity HTN-2 Investigators conducted a randomized controlled trial on renal sympathetic denervation)\n##\n(\"entity\"<|>SPYRAL HTN GLOBAL CLINICAL TRIAL PROGRAM<|>ORGANIZATION<|>The SPYRAL HTN Global Clinical Trial Program studies renal denervation in the absence and presence of antihypertensive medications)\n##\n(\"entity\"<|>SYMPLICITY HTN-3 TRIAL<|>ORGANIZATION<|>The SYMPLICITY HTN-3 trial is a randomized controlled trial on renal denervation for resistant hypertension)\n##\n(\"entity\"<|>RADIANCE-HTN SOLO<|>ORGANIZATION<|>RADIANCE-HTN SOLO is a multicentre, international, single-blind, randomised, sham-controlled trial on endovascular ultrasound renal denervation)\n##\n(\"entity\"<|>RADIANCE-HTN TRIO<|>ORGANIZATION<|>RADIANCE-HTN TRIO is a randomised, multicentre, single-blind, sham-controlled trial on ultrasound renal denervation for hypertension resistant to a triple medication pill)\n##\n(\"entity\"<|>TARGET BP I<|>ORGANIZATION<|>TARGET BP I is a randomized clinical trial on alcohol-mediated renal denervation)\n##\n(\"relationship\"<|>KRUM H<|>SYMPLICITY HTN-2 INVESTIGATORS<|>Krum H is a researcher involved in the Symplicity HTN-2 trial<|>8)\n##\n(\"relationship\"<|>ESLER MD<|>SYMPLICITY HTN-2 INVESTIGATORS<|>Esler MD is a researcher involved in the Symplicity HTN-2 trial<|>8)\n##\n(\"relationship\"<|>BHATT DL<|>SYMPLICITY HTN-3 TRIAL<|>Bhatt DL is a researcher involved in the SYMPLICITY HTN-3 trial<|>8)\n##\n(\"relationship\"<|>KANDZARI DE<|>SPYRAL HTN GLOBAL CLINICAL TRIAL PROGRAM<|>Kandzari DE is a researcher involved in the SPYRAL HTN Global Clinical Trial Program<|>8)\n##\n(\"relationship\"<|>MAHFOUD F<|>SPYRAL HTN GLOBAL CLINICAL TRIAL PROGRAM<|>Mahfoud F is a researcher involved in the SPYRAL HTN Global Clinical Trial Program<|>8)\n##\n(\"relationship\"<|>AZIZI M<|>RADIANCE-HTN SOLO<|>Azizi M is a researcher involved in the RADIANCE-HTN SOLO trial<|>8)\n##\n(\"relationship\"<|>AZIZI M<|>RADIANCE-HTN TRIO<|>Azizi M is a researcher involved in the RADIANCE-HTN TRIO trial<|>8)\n##\n(\"relationship\"<|>PATHAK A<|>TARGET BP I<|>Pathak A is a researcher involved in the TARGET BP I trial<|>8)\n##\n(\"relationship\"<|>WEBER MA<|>TARGET BP I<|>Weber MA is a researcher involved in the TARGET BP I trial<|>8)\n<|COMPLETE|>", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1751558908, "model": "deepseek-chat", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_8802369eaa_prod0623_fp8_kvcache", "usage": {"completion_tokens": 1577, "prompt_tokens": 2938, "total_tokens": 4515, "completion_tokens_details": null, "prompt_tokens_details": {"audio_tokens": null, "cached_tokens": 1792}, "prompt_cache_hit_tokens": 1792, "prompt_cache_miss_tokens": 1146}}, "input": {"messages": [{"content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: [306]  Krum H, SchlaichM, WhitbournR, etal. Catheter-basedrenal sympatheticdenervation for resistanthypertension: a multicen- tresafety and proof-of-principle cohort study[J]. Lancet, 2009,  373(9671) :1275-1281.\n[307]  Symplicity HTN-2 Investigators, Esler MD, Krum H,  et al.  SymplicityHTN-2Investigators. Renalsympathetic denervation inpatientswithtreatment-resistanthypertension(theSymplicity HTN-2trial) : a randomised controlled trial[J]. Lancet, 2010,  376(9756) :1903-1909.\n[308]  BhattDL, KandzariDE, O’NeillWW , etal. A controlled trial\n\n\n\nof renal denervation for resistant hypertension[J]. N EnglJ Med,2014,370(15) :1393-1401.\n[309]  Bhatt DL,  Vaduganathan M, KandzariDE, et al.  Long-term  outcomesaftercatheter-basedrenalarterydenervationforresist- ant   hypertension:    final   follow-up    of   the    randomised SYMPLICITY HTN-3trial[J]. Lancet,2022,400(10361) : 1405- 1416.\n[310]  KandzariDE, KarioK, MahfoudF, etal.  The SPYRALHTN  GlobalClinicalTrialProgram: rationaleanddesignforstudiesof renaldenervation in the absence (SPYRAL HTN OFF-MED)  and presence (SPYRAL HTN ON-MED)  of antihypertensive medications[J]. Am HeartJ,2016,171(1) :82-91.\n[311]  Townsend RR, MahfoudF, KandzariDE, etal. Catheter-based renaldenervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN- OFF MED) : a randomised, sham-controlled, proof-of-concept trial[J]. Lancet,2017,390(10108) :2160-2170.\n[312]  KandzariDE, B?hm M, MahfoudF, etal. Effectofrenalden- ervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial[J]. Lancet,  2018,391(10137) :2346-2355.\n[313]  MahfoudF, B?hm M, SchmiederR, etal.  Effectsofrenalden- ervation on kidneyfunction and long-term outcomes: 3-yearfol- low-upfrom theglobalSYMPLICITY registry[J]. EurHeartJ,  2019,40(42) :3474-3482.\n[314]  B?hm M, Kario K, KandzariDE, et al.  Efficacy of catheter- based renaldenervation in theabsenceofantihypertensivemedi- cations (SPYRAL HTN-OFF MED Pivotal) :  a multicentre,  randomised,  sham-controlled  trial [ J ].   Lancet,  2020,  395\n(10234) :1444-1451.\n[315]  MahfoudF, KandzariDE, KarioK, et al.  Long-term efficacy and safetyofrenaldenervation in thepresenceofantihypertens- ive drugs (SPYRAL HTN-ON MED) :  a randomised,  sham- controlledtrial[J]. Lancet,2022,399(10333) :1401-1410.\n[316]  AziziM, SchmiederRE, MahfoudF, etal. Endovascularultra- sound renal denervation to treat hypertension ( RADIANCE- HTN SOLO) : a multicentre, international, single-blind, ran- domised, sham-controlled trial[J]. Lancet, 2018, 391(10137) :  2335-2345.\n[317]  AziziM, SanghviK, SaxenaM, etal. Ultrasound renaldener- vation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO) : arandomised, multicentre, single- blind, sham-controlled trial[J]. Lancet,2021,397(10293) :2476- 2486.\n[318]  PathakA, RudolphUM, SaxenaM, etal. Alcohol-mediatedre- naldenervation in patients with hypertension in the absence of antihypertensivemedications[J]. EuroIntervention,2023,19(7) :  602-611.\n[319]  KandzariDE, Weber MA, PathakA, et al.  Effect of alcohol- mediated renaldenervation on blood pressure in the presence of antihypertensive  medications:    primary   results   from    the TARGET BP Ⅰ randomized clinicaltrial[J]. Circulation, 2024,  149(24) :1875-1884.\n[320]  KalarusZ, MerkelyB, Neu?ilP, etal. Pacemaker-basedcardiac\n\n\nneuromodulation therapy\n######################\nOutput:", "role": "user"}], "parameters": {"model": "deepseek-chat", "frequency_penalty": 0.0, "max_tokens": 4000, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0}}, "key": "chat_a0defc7b4725c1ccc3e65d28a81281f1c8924d1b39a80d273d80a8b89c042098_v2"}